Isatori 10-K 24 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 18, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	iSatori, Inc.
Entity Central Index Key	741114
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$3,359,740
Entity Common Stock, Shares Outstanding		13,373,791
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$738,725	$822,876
Investments	0	0
Accounts receivable trade	925,506	2,398,178
Income tax receivable	0	102,452
Note receivables - current portion	28,939	11,013
Inventories	2,483,602	1,985,764
Assets held for sale	34,979	108,228
Deferred tax asset, net	0	53,081
Prepaid expenses	217,668	222,466
Total current assets	4,429,419	5,704,058
Property and equipment:
Leasehold improvements	11,485	11,485
Furniture and fixtures	128,902	112,362
Office equipment	57,408	52,908
Computer equipment	332,171	312,403
Dies and cylinders	43,942	43,942
Less accumulated depreciation	-425,238	-359,464
Net property and equipment	148,670	173,636
Note receivable - net of current portion	52,695	81,714
Other assets:
Deferred tax asset, net	57,314	147,941
Deposits and other assets	45,207	61,167
Total other assets	102,521	209,108
Total assets	4,733,305	6,168,516
Current liabilities
Trade accounts payable	819,918	1,248,490
Accrued expenses	253,208	187,608
Deferred revenues	191,127	292,215
Deferred tax liability, net	57,314	0
Line of credit	1,620,519	1,220,655
Notes payable	15,708	20,464
Total current liabilities	2,957,794	2,969,432
Long-term liabilities
Derivative liability	152,849	471,015
Commitments and contingencies
Stockholders' Equity
Convertible preferred stock	225	225
Common stock	129,093	128,797
Additional paid-in-capital	4,796,241	4,731,535
Accumulated deficit	-3,302,897	-2,132,488
Total stockholders' equity	1,622,662	2,728,069
Total liabilities and stockholders' equity	$4,733,305	$6,168,516

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Convertible preferred stock, par value per share in dollars	$0.01	$0.01
Convertible preferred stock, shares authorized	750,000	750,000
Convertible preferred stock, shares issued	22,500	22,500
Convertible preferred stock, shares outstanding	22,500	22,500
Convertible preferred stock, liquidation value	$450,000	$450,000
Common stock, par value in dollars	$0.01	$0.01
Common stock, shares authorized	56,250,000	56,250,000
Common stock, shares issued	12,909,278	12,879,651
Common stock, shares outstanding	12,909,278	12,879,651

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Product revenue (Net of returns and discounts)	$9,513,606	$10,507,038
Royalty revenue	103,975	115,749
Other revenue	37,207	42,251
Total revenue	9,654,788	10,665,038
Cost of sales	4,727,660	4,686,708
Gross profit	4,927,128	5,978,330
Operating Expenses:
Selling and marketing	2,353,018	2,974,203
Salaries and labor related expenses	2,499,719	2,241,470
Administration	1,082,962	1,586,526
Depreciation and amortization	78,574	95,148
Total operating expenses	6,014,273	6,897,347
Loss from operations	-1,087,145	-919,017
Other income (expense)	300,800	74,346
Financing expense	-55,827	-78,533
Interest expense	-49,540	-32,610
Loss before income taxes	-891,712	-955,814
Income tax expense	-278,697	-2,828
Net loss	($1,170,409)	($958,642)
Net loss per common share, Basic	($0.09)	($0.08)
Net loss per common share, Diluted	($0.09)	($0.08)
Weighted average shares outstanding, Basic	12,890,840	12,763,946
Weighted average shares outstanding, Diluted	12,890,840	12,763,946

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)	Preferred Stock ($0.01 Par)	Common Stock ($0.01 Par)	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Total
Beginning balance at Dec. 31, 2012	$225	$126,228	$4,343,069	($1,173,846)	$3,295,676
Beginning balance, shares at Dec. 31, 2012	22,500	12,622,756
Net loss				-958,642	-958,642
Share based compensation, value			320,050		320,050
Exercise of Warrants/Options, value		2,495	52,239		54,734
Exercise of Warrants/Options, shares		249,508
Issuance of shares to the Board of Directors, value		74	16,177		16,251
Issuance of shares to the Board of Directors, shares		7,387
Ending balance at Dec. 31, 2013	225	128,797	4,731,535	-2,132,488	2,728,069
Ending balance, shares at Dec. 31, 2013	22,500	12,879,651			12,879,651
Net loss				-1,170,409	-1,170,409
Share based compensation, value		75	48,707		48,782
Share based compensation, shares		7,500
Issuance of shares to the Board of Directors, value		221	15,999		16,220
Issuance of shares to the Board of Directors, shares		22,127
Ending balance at Dec. 31, 2014	$225	$129,093	$4,796,241	($3,302,897)	$1,622,662
Ending balance, shares at Dec. 31, 2014	22,500	12,909,278			12,909,278

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($1,170,409)	($958,642)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	78,574	95,148
Share based compensation expense	55,790	336,300
Change in value of assets held for sale	-14,594	-105,809
Change in fair value of derivative liability	-318,166	-143,082
Provision for (benefit from) deferred income taxes	258,026	-17,501
Change in assets and liabilities:
Accounts receivable	1,472,672	-1,157,442
Notes receivable	11,093	-1,163
Inventory	-497,838	-693,659
Prepaid expenses	14,010	-66,035
Deposits and other assets	3,163	-13,836
Trade accounts payable	-428,572	730,340
Accrued expenses	65,600	-54,693
Deferred revenues	-101,088	292,215
Income taxes	45,448	0
Net cash used in operating activities	-526,291	-1,757,859
Cash flows from investing activities:
Purchase of property and equipment	-40,811	-135,822
Proceeds from the sale of assets held for sale	87,843	26,919
Sale of investments	0	965,886
Net cash provided by (used in) investing activities	47,032	856,983
Cash flows from financing activities:
Proceeds from notes payable	0	25,101
Payment of notes payable	-4,756	-4,637
Proceeds from line of credit	411,000	97,500
Repayment of line of credit	-11,136	-50,000
Proceeds from the exercise of warrants	0	335
Net cash provided by financing activities	395,108	68,299
Net increase (decrease) in cash	-84,151	-832,577
Cash and cash equivalents, beginning of year	822,876	1,655,453
Cash and cash equivalents, end of year	738,725	822,876
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	58,783	49,761
Cash paid for taxes	10,760	6,863
Non-cash transactions
Decrease in warrant derivative liability due to warrant exercise	0	87,755
Decrease in deferred tax asset due to warrant exercise	0	33,355
Cashless exercise of options/warrants	0	2,161
Issuance of shares to the Board of Directors	$296	$73

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 1 - Summary of Significant Accounting Policies
	Organization and Nature of Business
	iSatori,Inc. (the “Company”) was incorporated under the laws of the state of Delaware on June 29, 2012. The trading symbol of the Company on OTCBB is “IFIT”.
	The Company is engaged in researching, designing, developing, contracting for the manufacture, marketing, selling and distributing of various branded nutritional and dietary supplement products for the general nutrition market. The “general nutrition market” may include such activities as body-building, physique enhancement (increase of lean body mass and decrease in fat mass) and enhanced athletic performance through increased strength and/or endurance and proper nutrition.
	The Company does engage from time to time in funding of clinical studies with the objective of discovering and/or validating claims of new, efficacious products for the Company’s relevant market as well as providing necessary and appropriate substantiation for any claims which the Company may use in its marketing and advertising. The Company markets products which are under its control and which are in some way proprietary to the Company. Some of the Company’s products are the subject of trademarks owned by the Company.
	Basis of Presentation
	The accompanying financial statements have been prepared on an accrual basis of accounting in accordance with Generally Accepted Accounting Principles in the United States (“GAAP”). The accompanying financial statements present the financial position and results of operations of the Company.
	Financial Instruments
	The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Accordingly, cash and cash equivalents consist of petty cash, checking accounts and money market funds.
	Fair Value Measurements
	Accounting Standards Codification (“ASC”) 820-10 establishes a framework for measuring the fair value of assets and liabilities and requires additional disclosure about fair value measurements. ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal (or most advantageous market) for the asset or liability in than orderly transaction between market participants at the measure date.
	The Company has a number of financial instruments, including cash, receivables, inventory, payables and debt obligations. The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued expenses, the line of credit and notes payable approximates their fair values because of the short maturity of these instruments. As further described in Note 7 the Company has issued warrants which are measured at fair value on a recurring basis and result in a long-term derivative liability on the balance sheet. The actual and estimated fair values, respectively, of the Company’s financial instruments are as follows:
		31-Dec-14					31-Dec-13
		Carrying			Fair Value		Carrying		Fair Value
		Value					Value
	Cash and cash equivalents	$	738,725		$	738,725	$	822,876	$	822,876
	Accounts Receivables	$	925,506		$	925,506	$	2,398,178	$	2,398,178
	Accounts payable	$	819,918		$	819,918	$	1,248,490	$	1,248,490
	Derivative liability	$	152,849		$	152,849	$	471,015	$	471,015
	Trade Receivables and Credit Policy
	Trade receivables are uncollateralized customer obligations due under normal trade terms requiring payment generally within 10-60 days from the invoice date. Accounts are considered delinquent when outstanding for more than seven days past due date. The Company does not have a policy of accruing interest on past due accounts. Payments on trade receivables are applied as instructed per the customer, or to the earliest unpaid invoices. The allowance for doubtful accounts represents an estimate of amounts considered uncollectible and is determined based on management’s historical collection experience, adverse situations that may affect the customer’s ability to repay, and prevailing economic conditions. Specific accounts deemed uncollectible are written off periodically with subsequent receipts on previously written off accounts credited to bad debt expense. The allowance for doubtful accounts is $0 for each of the periods ended December 31, 2014 and December 31, 2013. Receivables at each of the below respective periods consisted of the following:
		December 31,			December 31,
		2014			2013
	Trade Receivables	$	951,396		$	2,323,522
	Other	$	-25,890		$	74,656
	Allowance for doubtful accounts	$	0		$	0
	Totals	$	925,506		$	2,398,178
	In addition, the Company has recorded an allowance for customer returns in the amount of approximately $85,000 at December 31, 2014 and $70,000 at December 31, 2013 in accrued expenses.
	Inventory Valuation
	Inventories of nutritional and dietary supplements are stated at lower of cost or market on a first-in, first-out (FIFO) basis as noted below:
		December 31,			December 31,
		2014			2013
	Labels and packaging	$	170,435		$	120,057
	Raw materials	$	308,333		$	207,320
	Finished goods	$	2,004,834		$	1,658,387
	Totals	$	2,483,602		$	1,985,764
	Notes Receivable
	The Predecessor Company disposed of a dormant product line of vitamins in December 2010. As part of the consideration in this divestiture, the Company received from the purchaser of this product line an unsecured note in the amount of $ 170,000. The original note was due to be repaid on or before March 2014, where interest accrued principally at an annual rate of 5%, based upon the initial $170,000 principal and was payable monthly. As of March 31, 2013, the note was novated and a new promissory note was issued to reflect a modification in the payment terms, which includes no interest. The total note receivable balance at December 31, 2014 was $81,634, and is due to be repaid in monthly increments through May 1, 2017.
	Property and Equipment
	Property and equipment are stated at cost. Depreciation for financial accounting purposes is computed using the straight-line method over the estimated lives of the respective assets, ranging from three to ten years. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are thereafter removed from the respective accounts and any gain or loss is credited or charged to income. Total depreciation expense was $65,774 and $83,450 for the years ended December 31, 2014 and 2013, respectively.
	Other Assets and Intangible Assets
	Other assets include intangible assets which are principally direct television advertising, websites, as well as deposits and are included in Deposits and other Assets. The Company periodically performs reviews of other assets including amortizable intangible and depreciable tangible assets, for impairment purposes using undiscounted cash flow methodology. Factors considered important that may trigger an impairment of assets review include, but are not necessarily limited to: significant changes in the manner of the use of its assets involving its strategy for its overall business; significant negative industry or economic trends; or underperforming business trends. These reviews may include an analysis of the Company’s current operations and capacity utilization in conjunction with an analysis of the markets in which the Company’s business is operating.
	Intangible assets are discussed below. Amortization for financial accounting purposes is computed using the straight-line method over the estimated useful lives of the respective assets which range from three to ten years. Amortization for 2014 and 2013 totaled $12,800 and $11,698, respectively.
		Balance at			Balance at
		31-Dec-14			31-Dec-13
	Amortized intangible assets:
	Website	$	38,355		$	38,355
	Patents	$	341		$	341
	Trademarks	$	100		$	100
	TOTAL	$	38,796		$	38,796
	Accumulated Amortization	$	-24,890		$	-12,090
	TOTAL	$	13,906		$	26,706
	Future Amortization for the years ending December 31:
	2015	$	12,785
	2016	$	1,121
	Revenue Recognition
	The Company operates predominantly as a distributor of its dietary supplement products through traditional large retailers and electronic intermediaries. Revenue from product sales is recognized upon transfer of title of the Company’s product to its customers. Net sales represent product sales less actual returns, allowances, discounts, and product promotions. Sales to direct customers have an unconditional money back guarantee for thirty to ninety days after the date of purchase. Sales to a select number of retail customers carry a “Sale or Return” Purchase agreement per the sales contract, where if minimum sales thresholds are not met within a required timeframe, the inventory will be returned to the Company for full credit. Other retail customers receive a percentage discount from invoice to cover any customer returns or damages they may incur. Returns, trade allowances, discounts and product promotions, were $2,656,122 and $2,114,060 for the years ending December 31, 2014 and 2013, respectively.
	In addition, the Company provides allowances for sales returns based upon estimated and known returns. Product returns are recorded as a reduction of net revenues and as a reduction of the accounts receivable balance.
	The Company receives other revenues which includes but is not limited to shipping and handling charges which is charged to customers.
	Cost of Sales
	The Company purchases its products directly from third party manufacturers. The Company’s cost of sales include product costs, including any associated materials used in production, cost of warehousing and distribution. Included in the cost of sales are transit freight shipping and handling costs that are incurred by the Company.
	Income Taxes
	The Company utilizes the asset and liability method of accounting for income taxes. Under this asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. See Note 6, “Income Taxes”.
	Since 2012 was the Company’s initial tax year, there are no prior federal or state tax returns subject to examination. Accordingly, the only taxable periods subject to examination by federal and state taxing authorities are the periods ended December 31, 2014, 2013 and 2012. Federal and state tax returns for the Company prior to the short form merger are open for the period ended December 31, 2011.
Leases
The Company leases its headquarters facility the “headquarters lease”, comprising approximately 10,044 square feet, in Golden (metropolitan Denver), Colorado. The total rent expense under the headquarters lease for each of the years ended December 31, 2014 and 2013 was $82,863. The lease term expires January 31, 2017 and requires equal monthly payments over the remaining term. Future payments under the headquarters lease are $172,632.
On November 1, 2014, the Company entered into a lease for approximately 17,026 square feet in Denver for its warehouse operations (the “warehouse lease”. The total rent expense under the warehouse lease for the year ended December 31, 2014 was $0. The lease term expires on December 31, 2018 and calls for inflation-adjusted increasing payments over the remaining term. Future payments under the warehouse lease are $374,658.
The Company also leases miscellaneous office and warehouse equipment. In most cases, management expects that in the normal course of business these leases will be renewed or replaced by other leases as applicable.
Future Payments
2015		$	169,993
2016		$	174,350
2017		$	102,748
2018		$	100,199
Total		$	547,290
Marketing
The Company expenses all production costs related to advertising costs as they are incurred, including print, digital and television when the advertisement has been broadcast or otherwise finished and or distributed. The Company records website costs related to its direct-to-consumer advertisements in accordance with ASC 340-20 “Capitalized Advertising Costs”. In accordance with ASC 340-20, direct response advertising costs incurred should be reported as assets and should be amortized over the estimated period of the benefits, based on the proportion of current period revenue from the advertisements to probable future revenue. As of December 31, 2014 and December 31, 2013, the Company had deferred $0 and $7,651 respectively, related to such advertising costs. This amount was included in Deposits and other assets and was amortized over a one year period. Total Marketing expenses for the years ended December 31, 2014 and 2013, totaled $1,500,362 and $2,232,548, respectively.
Research and Development Costs
Research and development costs, which include the funding of clinical research studies, as well as creation and development of new products, are expensed when incurred. Research and development costs of $99,676 and $162,297 for the years ended December 31, 2014 and 2013, respectively, are included in selling and marketing expense.
Distribution, Shipping and Handling Costs
Shipping costs on purchases and shipping and handling fees related to sales charged to customers are both included in cost of sales. As mentioned in Revenue Recognition, shipping and handling revenue billed customers are reflected in other revenues.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of temporary cash investments and trade accounts receivables. Concentrations of credit with respect to trade receivables are limited due to the large number of customers comprising the Company’s customer bases and their dispersion across different geographic locations.
The Company maintains cash balances at one financial institution located in Colorado and one in California. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 per account. At times during the year, the Company’s bank balances have exceeded the FDIC limit. Management believes the risk of loss at such institutions to be minimal.
During the year ended December 31, 2014, sales to three customers made up 57% of total product revenue, with each customer representing greater than 10% of product revenue on an individual basis. These customers’ combined accounts receivable balances were 51% of total accounts receivable as of December 31, 2014. During the year ended December 31, 2013, sales to three customers made up 58% of total product revenue, with each customer representing greater than 10% of product revenue on an individual basis. These customers’ combined accounts receivable balances were 73% of total accounts receivable as of December 31, 2013.
During the year ended December 31, 2014, purchases from three vendors made up 63% of total inventory purchases. These vendors’ combined accounts payable balances were 44% of total accounts payable as of December 31, 2014. During the year ended December 31, 2013, purchases from two vendors made up 57% of total inventory purchases. These vendors’ combined accounts payable balances were 17% of total accounts payable as of December 31, 2013.
Use of Estimates
The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include but are not limited to the fair value determination of derivative instruments, NOL allowance, sales returns allowance, allowance for notes receivable and the realizable value of inventories.
Earnings (Loss) Per Share
Net earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.
Since the Company reflected a net loss for the years ended December 31, 2014 and 2013, the effect of considering any common stock equivalents, if exercisable, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.
The Company has the following common stock equivalents as of December 31, 2014 and December 31, 2013:
		2014		2013
In the money stock options		593,081		669,963
In the money warrants		420,549		928,881
Total common stock equivalents		13,689,208		13,862,892
Recent Accounting Pronouncements
In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-15, Presentation of Financial Statements - Going Concern. The objective of ASU 2014-15 is to provide guidance on management’s responsibility to evaluate whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for fiscal years ending after December 15, 2016, and annual and interim periods thereafter. The Company is currently evaluating impact of the adoption of this standard and do not expect it to have a significant impact on its financial statements.
In May 2014, the FASB issued ASU 2014-09, which establishes a comprehensive new revenue recognition standard designed to depict the transfer of goods or services to a customer in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under current revenue recognition guidance. The ASU allows for the use of either the full or modified retrospective transition method, and the standard will be effective for us in the first quarter of 2017 unless a deferral for adoption is provided by the FASB; early adoption is not permitted. The Company is currently evaluating which transition approach to use and the impact of the adoption of this standard on its financial statements.

Endorsement_Spokesperson_Consu

Endorsement / Spokesperson / Consulting Agreements	12 Months Ended
	Dec. 31, 2014
Marketing and Advertising Expense [Abstract]
Endorsement / Spokesperson / Consulting Agreements	Note 2 - Endorsement / Spokesperson / Consulting Agreements
	The Company is obligated under various endorsement, spokesperson and consulting agreements with varying original terms ranging from six months to one year. These endorsers, spokespersons and consultants are generally paid a monthly fee for their services, including promotion and marketing activities per the agreements. All of these agreements may be terminated by either party upon breach or default in the terms of the agreements. The Company expensed $102,650 and $161,950 under these agreements in 2014 and 2013, respectively.
	Future payments of the above mentioned contracts will run through 2015, for a total expense of $18,000.

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Retirement Plan	Note 3 - Retirement Plan
	Eligible employees may enroll in a company-sponsored 401(k) plan. New enrollees are able to join the plan in the calendar quarter in which they become eligible. The Company may also make a match at its discretion. During calendar years 2014 and 2013, there were no matches under this plan made by the Company.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2014
Loss Contingency [Abstract]
Contingencies	Note 4 - Contingencies
	In accordance with the accounting standards on contingencies, the Company accrues a loss contingency if it is probable and can reasonably be estimated or a liability has been incurred at the date of the financial statements. If both of these conditions are not met, or if an exposure to loss exists in excess of the amount accrued, disclosure of the contingency shall be made when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. The Company is exposed to legal claims encountered in the normal course of business. See Note 5, “Litigation”. Management believes that the ultimate resolution of these matters will not have a material adverse effect on the operating results or the financial position of the Company.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Litigation	Note 5 - Litigation
	The Company is engaged in various legal actions, claims and proceedings arising in the normal course of business, including claims related to breach of contracts, product liabilities and intellectual property matters resulting from the Company’s business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. The following summaries highlight the current status of certain material commercial litigation in which the Company is involved.
	On May 17, 2013 and on January 31, 2014 the Company received demand letters from the Environmental Research Corporation, “ERC” requesting substantiation of compliance with the State of California’s Proposition 65 regulations for ten of its products. In October, while the Company was awaiting the results of the compliance testing, ERC contacted the Company again requesting settlement to their initial demand letter. And in February 2014, before compliance testing or any other demand letter validation was completed, ERC contacted the Company again requesting settlement to their second demand letter. After many discussions with ERC, a lawsuit was filed by ERC for the non-compliance issues with the State of California’ Proposition 65 regulations. After many conversations and mediation attempts, both parties have agreed to a settlement, which has been approved by the iSatori Board of Directors. The documents are currently being generated for presentation to the California Court. Once accepted by the court, settlement amounts will be paid. This action is expected to happen in second quarter of 2015. The Company believes this settlement of the lawsuits is in the best interest of iSatori. Settlement amounts have been accrued into FY 2014 and are reflected in this 10K report.
	On March 24, 2014 the Company received a summons in a civil action filed by Wise Sports Nutrition, LLC claiming alleged trademark infringement for iSatori’s, Garcinia Trim product. Company counsel has made contact with the plaintiff’s attorney and filed a response to the alleged trademark infringement with the Company’s counterclaims. The Company believes the counterclaims have strong merit and are pursuing their defense. Both parties have prepared responses and presented them to the court. The court has recently ruled in favor of iSatori and its filing of a summary judgment. As a result of this ruling the trademark has been ruled as “descriptive” and therefore not eligible for trademark assignment. iSatori has been contacted by the former plaintiff in this case to discuss a favorable settlement with iSatori. Settlement discussions will get underway promptly. The Company believes now that a favorable condition exists for settlement but it is too early in the settlement proceedings to make a determination of the outcome. Therefore, no range of any possible gain or loss can be reasonably estimated as of the date of the financial statements.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 6 - Income Taxes
	For the years ended December 31 2014, and 2013, the Company recognized income tax expense of $278,697 and $2,828, respectively.
	At December 31, 2014 and 2013, management believes there are no uncertain tax liabilities. The Company recognizes interest and penalties related to uncertain tax positions in income tax (benefit)/expense. No interest and penalties related to uncertain tax positions were accrued at December 31, 2014 or 2013.
	The Company files income tax returns in U.S. federal jurisdiction and various states. There are currently no federal or state income tax examinations underway for these jurisdictions. The 2014 tax year remains open to examination by taxing jurisdictions to which the Company is subject.
	Income tax provision for the periods December 31, 2014 and December 31, 2013 consists of the following:
		12/31/14			12/31/13
	Current tax expense (benefit)
	Federal	$	67,026		$	18,438
	State		10,649			1,890
			77,675			20,328
	Deferred tax expense (benefit):
	Federal		185,106			-18,756
	State		15,916			1,256
			201,022			-17,500
	Total	$	278,697		$	2,828
	The reconciliations of the results of applying the Company's effective statutory federal income tax rate of 35% for the years ended December 31, 2014 and December 31, 2013 to the Company's income before taxes and the Company's provision for income taxes are as follows:
		12/31/14		12/31/13
	Federal income taxes	35.00%		35.00%
	State income taxes	2.81%		2.18%
	Permanent items	-2.29%		-9.60%
	Current year losses not utilized	-61.04%		-27.90%
		25.51%		0.30%
	The components of the deferred tax assets, net of deferred tax liabilities for each period are:
		12/31/14			12/31/13
	Inventory	$	42,109		$	32,709
	Allowance for doubtful accounts		32,132			26,506
	Deferred revenue		72,646			111,069
	Other		32,147			9,865
	Valuation allowance		-167,394			-
	Current Deferred Tax Assets		11,640			180,149
	Net operating loss		772,088			410,140
	Foreign tax credits		29,211			-
	Fair value of derivatives		58,097			179,030
	Share based compensation		21,505			21,589
	Property and equipment		22,366			-
	Valuation allowance		-844,543			-410,140
	Long term deferred tax assets		58,724			200,619
	Total deferred tax assets		70,364			380,768
	Unrealized gain on marketable securities		-13,295			-41,137
	Prepaid expenses		-55,659			-85,931
	Current deferred tax liabilities		-68,954			-127,068
	Property & equipment		-			-43,853
	Goodwill and other intangibles		-1,410			-8,825
	Long term deferred tax liabilities		-1,410			-52,678
	Total deferred tax liabilities		-70,364			-179,746
	Net Deferred tax asset	$	-		$	201,022
	As of December 31, 2014, the Company has federal and state income tax net operating loss (NOL) carry forwards of $2,031,303 which will expire at various dates from 2032 through 2034. The NOLs are projected to expire as follows:
	2032		$	434,814
	2033			466,786
	2034			1,129,703
			$	2,031,303
	NOL from Predecessor Company
	At December 31, 2014, approximately $8.208 million of net operating loss carry forwards for federal income tax purposes and approximately $8.208 million of net operating loss carry forwards for state income tax purposes, existed and were previously generated by a predecessor company. The Tax Reform Act of 1986 contains provisions that limit the utilization of net operating loss and tax credit carry forwards if there has been a change of ownership as described in Section 382 of the Internal Revenue Code. According to a preliminary analysis performed by the Company, it was determined that these net operating loss carry forwards would not currently be available for utilization by the Company. As such, these net operating loss carry forwards which had previously been 100% allowed for, have been removed from the deferred tax assets. The availability of the net operating loss carry forwards may be analyzed further in future accounting periods. If a positive determination is made, the net operating loss carry forwards might then be reported as deferred tax assets of the Company.
	NOL from iSatori
	Based upon past financial performance, the company has not been able to utilize certain NOL carry forwards. In recognition of this risk, at December 31, 2014, and 2013, a valuation allowance of $844,543 and $410,140, respectively, has been recognized on the deferred tax assets relating to the net operating loss carry forwards. Should future financial performance change and it is determined the Company can realize the use of these net operating losses, the appropriate tax expense and equity adjustments will be made.
	In addition to the valuation allowance offsetting the deferred tax assets arising from net operating loss carry forwards, at certain other deferred tax assets at December 31, 2014 have been reduced by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. Should the Company achieve sufficient, sustained income in the future, some or all of the valuation allowances may be reversed.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	Note 7 - Stockholders’ Equity
	At December 31, 2014, there were 12,909,278 shares of common stock, par value $.01 per share, outstanding for the Company.
	Warrants
	As of December 31, 2014, there were common stock warrants outstanding to purchase aggregate shares of common stock pursuant to the warrant grants described below.
	On July 15, 2011 the Company issued warrants, now totaling 420,549 shares, to purchase 3% of fully diluted shares of the common stock of the Company to Breakwater Structured Growth Opportunity Fund, L.P., (the “Breakwater warrant”) with an imputed exercise price equal to approximately one-hundredth of a dollar in connection with a $1.025 million subordinated mezzanine loan arrangement. These warrants are fully vested and expire on June 15, 2016.
	Included in the aforementioned Breakwater warrant, was an obligation by the Company to, among other things, honor an irrevocable put right through which the Company agreed to purchase up to the 3% of fully diluted shares of its common stock underlying the warrant, which expires on July 15, 2016. Upon completion of the Merger, the irrevocable put right was removed.
	The Company used a lattice model in developing a fair value for the Breakwater warrant obligation at December 31, 2014, using a quoted stock value of $.375 per share, which represents a discount of 50% from the closing stock price. This reduction was based on the application of a discount for lack of liquidity. Other assumptions used in the valuations include (a) risk free interest rate of .67% based on duration, (b) weighted average expected term in years of 1.58, (c) weighted average expected stock volatility of 37.13%, (d) expected dividends of 0% (e) stock price movements ranging from 1.053 to .950 and (f) risk neutral probabilities ranging from .488 to .512. These valuations resulted in net income of $318,166 and in the Statement of Operations for the year ended December 31, 2014. In addition, as of June 28, 2013, $87,755 was reclassified to additional paid in capital from derivative liability due to the exercise of a prior warrant, and revaluations resulted in net income of $143,082 in the Statement of Operations for the year ended December 31, 2013.
	Effective January 1, 2013, the Company entered into a one year agreement, subject to quarterly cancellation at the Company’s sole discretion, with Microcap Headlines, Inc. In connection with this agreement, the Company issued warrants to purchase an aggregate of 100,000 shares of the Company’s common stock at an exercise price of $2.25 per share (the “Microcap warrants”). These warrants were subject to conditional vesting schedule in one-fourth (quarterly) increments, subject to the Company’s sole discretion. The first increment was granted and fully vested on January 1, 2013, the second increment was granted and fully vested on April 1, 2013, the third increment was granted and fully vested on July 1, 2013, and the fourth increment was granted and fully vested on October 1, 2013. These vested warrants expire on January 1, 2018.
	Effective July 16, 2013, the Company entered into a business consulting agreement with Optivest Global Partners, LLC. In connection with this agreement, the Company issued warrants to purchase an aggregate of 250,000 shares of the Company’s common stock at an exercise price of $2.25 per share (the “Optivest warrants”). These warrants are fully vested and expire July 16, 2018. These warrants will be assignable and transferable, at Optivest’s discretion.
	The fair value of the Microcap and Optivest warrants were estimated on the date of grant using the Black-Scholes option-pricing model.
	The Black-Scholes assumptions used when the warrants were issued are as follows:
		FY 2013
	Exercise price	$	2.25
	Expected dividends		0	%
	Expected volatility		45.95-48.97	%
	Risk fee interest rate		0.72-1.42	%
	Expected life		5 years
	Expected forfeiture		0	%
	The Company assumed the 1,069,587 outstanding warrants to purchase shares of Common Stock which were issued by Integrated in fiscal years 2009 and before. Of these, 17,230 expired on July 29, 2012 and the remainder expired on May 31, 2014.
	The following is a summary of the Company’s warrant activity:
			Warrants		Weighted Average			Weighted Average
					Exercise Price			Remaining
								Contractual Life
	Balance – December 31, 2012		225,000			2.36		6.08 years
	Granted		350,000		$	2.25		4.42 years
	Exercised		-			-
	Forfeited/cancelled		-			-
	Balance – December 31, 2013		575,000			2.29		5.05 years
	Granted		-			-
	Exercised		-			-
	Forfeited/Cancelled		-			-
	Balance – December 31, 2014 – outstanding		575,000		$	2.29		4.05 years
	Balance – December 31, 2014 – exercisable		575,000		$	2.29		4.05 years
	2012 Performance Incentive Plan
	On September 27, 2012, the Company’s Board of Directors approved the 2012 Performance Incentive Plan (the Plan”). The Plan allows the Company to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. Any stock option granted in the form of an incentive stock option will be intended to comply with the requirements of Section 422 of the Code. Only stock options granted to employees qualify for incentive stock option treatment. A stock option may be exercised in whole or in installments, which may be cumulative. Shares of common stock purchased upon the exercise of a stock option must be paid for in full at the time of the exercise in cash or such other consideration determined by the compensation committee. Payment may include tendering shares of common stock or surrendering of a stock award, or a combination of methods.
	The Plan is administered by the Plan Administrator, being the Board or one or more committees appointed by the Board or another committee (within its delegated authority) to administer all or certain aspects of this Plan. The Administrator has full and exclusive power within the limitations set forth in the Plan to make all decisions and determinations regarding the selection of participants and the granting of awards; establishing the terms and conditions relating to each award; adopting rules, regulations and guidelines; and interpreting the Plan.
	On January 2, 2014, the Company issued options to purchase 10,000 shares of the Company’s common stock to an employee with an exercise price of $2.50 per share and which contained three year vesting schedules of 1/3 each year through October 2016. These options were due to expire on October 15, 2023. In September 2014, upon termination of employment prior to vesting, these options were forfeited.
	On February 10, 2014, the Company issued options to purchase 6,000 shares of the Company’s common stock to an employee with an exercise price of $2.22 per share and which contain three year vesting schedules of 1/3 each year through February 2017. These options were due to expire on February 10, 2024. In December, 2014, upon termination of employment prior to vesting, these options were forfeited.
	On September 17, 2013, the Company issued options to purchase 50,000 shares of the Company stock to an employee, having an exercise price of $2.10, and which contain three year vesting schedules of 1/3 each year through September 2015. These options are due to expire on September 17, 2023.
	The Company applied fair value accounting for all share based payment awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model. The total valuation of the options granted in 2014 was $3,363. Due to their forfeiture prior to vesting, expense of $747 recognized in previous quarters of 2014 was reversed within subsequent periods of 2014, for a net expense of $0 related to 2014 grants for the year ended December 31, 2014. The total valuation of the options granted in 2013 was $30,985, which is being expensed over the three year vesting period. The expense recognized related to these options for the year ended December 31, 2014 was $10,328. The Black-Scholes assumptions used when the options were issued are as follows:
			FY 2014				FY 2013
	Exercise price	$	2.22-2.50			$	2.1
	Expected dividends		0	%			0	%
	Expected volatility		35.22	%			45.95	%
	Risk fee interest rate		2.13-2.41	%			2.26	%
	Expected life of option		6.08-6.33 years				5.5-6.5 years
	Expected forfeiture		0	%			0	%
	The following is a summary of the Company’s stock option activity:
			Options		Weighted Average			Weighted Average
					Exercise Price			Remaining
								Contractual Life
	Balance – December 31, 2012		828,174			0.683		9.14 years
	Granted		50,000		$	2.1		9.75 years
	Exercised		-137,577			0.621
	Forfeited/cancelled		-9,908			2.25
	Balance – December 31, 2013		730,689		$	0.771		8.30 years
	Granted		16,000		$	2.4		9.75 years
	Exercised
	Forfeited/cancelled		-16,000		$	2.4		9.75 years
	Balance – December 31, 2014 – outstanding		730,689		$	0.771		7.30 years
	Balance – December 31, 2014 – exercisable		637,159			0.683		7.25 years
	Outstanding options held by related parties – 2014		730,689
	Exercisable options held by related parties – 2014		637,159
	In addition to the above, for the year ended December 31, 2014, the Company has recognized $12,619 in share based compensation expense arising from the amortization of option awards granted prior to January 1, 2013.
Stock Awards
On July 10, 2014, the Company issued 5,603 shares of restricted stock to members of its board of directors. On September 23, 2014, the Company issued 4,098 shares of restricted stock to a new member of its board of directors. On October 28, 2014, the Company issued 7,738 shares of restricted stock to members of its board of directors. On November 13, 2014, the Company issued 4,688 shares to a new member of its board of directors. The Company is amortizing total expense related to these issuances over the restriction period which is equivalent to the directors’ one-year term. The Company has recorded share based compensation expense due to these issuances of $16,568 for the year ended December 31, 2014. In addition, for the year ended December 31, 2014, the Company has amortized prior expense of $9,212 to equity related to grants of restricted stock made prior to January 1, 2014.
On April 1, 2014, the Company issued 7,500 shares of its $.01 par value common stock to a business development consultant. The Company considered the fair value of the shares issued to be the most reliable measure of compensation to the consultant. At the time of issuance, the Company’s stock price was $2.17 per share, and therefore the issuance resulted in $16,275 of share based compensation expense for the year ended December 31, 2014.

Convertible_Preferred_Stock

Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2014
Convertible Preferred Stock
Convertible Preferred Stock	Note 8 - Convertible Preferred Stock
	In connection with the Merger, the Company assumed into its capital structure the convertible stock originally issued by Integrated. Accordingly, at December 31, 2014, the Company’s convertible preferred stock, $0.01 par value per share, consisted of the following:
		Par Value		Shares	Liquidation
				Outstanding	Preference
	Series A $20	$	95	9,500	$	190,000
	Series D $20		130	13,000		260,000
		$	225	22,500	$	450,000
	Series A $20 Convertible Preferred Stock. At December 31, 2014, the Company had 9,500 shares of its Series A $20 Convertible Preferred Stock (the “Series A Preferred”) outstanding. Holders of the Series A Preferred are not entitled to receive any dividends, and have no voting rights unless otherwise required pursuant to Delaware law. Each share of the Series A Preferred may, at the option of the Company, be converted into the equivalent of one-fifth (1/5th) of a share of common stock at any time after (i) the closing bid price of the common stock is at least $2.00 for at least 20 trading days during any 30 consecutive trading day period, and (ii) the shares of common stock to be received on conversion have been registered or otherwise qualified for sale under applicable securities laws. The holders of the Series A Preferred have the right to convert each share into the equivalent of one-fifth (1/5th) of a share of common stock at any time. Upon any liquidation, dissolution, or winding up of the Company, the holders of the Series A Preferred are entitled to receive $20 per share before the holders of common stock are entitled to receive any distribution. In the event the Company enters into any consolidation, merger or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or other securities, each share of Series A Preferred will at the same time be similarly exchanged or changed into such consideration as is equal to four times the amount of consideration to be received for each share of common stock.
	Series D $20 Convertible Preferred Stock. At December 31, 2014 the Company had 13,000 shares of its Series D $20 Convertible Preferred Stock (the “Series D Preferred”) outstanding. Holders of the Series D Preferred are entitled to receive, out of funds of the Company legally available, dividends at the annual rate of $1.80 per annum per share.
	The Company may redeem the Series D Preferred upon not less than 30 days’ notice, in whole or in part, for an amount of $20 per share plus all accrued but unpaid dividends applicable to such share. After notice and prior to the expiration of the 30-day notice period, holders of the Series D Preferred will have the option to convert the Series D Preferred into common stock prior to the redemption. Each share of the Series D Preferred may, at the option of the Company, be converted into the number of shares of common stock as determined by dividing $20 plus any accrued and unpaid dividends on such share by $80 at any time after (i) the closing bid price of the common stock exceeds $200.00 for 20 consecutive trading days, and (ii) the Company has sustained positive earnings per share of common stock for the two previous fiscal quarters. The holders of the Series D Preferred have the right to convert each share at any time into the number of shares of common stock as determined by dividing $20 plus any accrued and unpaid dividends on such share by $80. The holders of the Series D Preferred are entitled to receive $20 per share plus any accrued and unpaid dividends on such share before the holders of common stock are entitled to receive any distribution. In the event the Company enters into any consolidation, merger or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or other securities, each share of Series D Preferred will at the same time be similarly exchanged or changed into the aggregate amount of stock as would have been received had the holder converted such shares immediately prior to the transaction.

Revolving_Line_of_Credit_and_R

Revolving Line of Credit and Related Interest	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Revolving Line of Credit and Related Interest	Note 9 - Revolving Line of Credit and Related Interest
	The Company entered into a renewed and expanded Credit Agreement with Colorado Business Bank West of Denver, Colorado on August 27, 2014. Borrowings under this agreement will be used to provide ongoing working capital and for other general corporate purposes of the Company and its subsidiaries.
	The agreement provides a revolving commitment to the Company of $2,000,000. Amounts outstanding under the agreement will be reflected in a promissory note with a principal balance of $2,000,000 and a maturity date of November 16, 2015 (the “Promissory Note”). The principal balance on the Promissory Note bears interest at the one month USD LIBOR rate measured not more often than once per month (the “Index”). Interest on any unpaid balance under the promissory note will bear interest at the Index plus 3.75% with a minimum interest rate of 4.00% per annum, and is payable monthly. The agreement requires the Company to comply with certain affirmative covenants, including a minimum current ratio of 1.5 to 1, a maximum leverage ratio of 2 to 1, and minimum tangible equity capital of $2,750,000 through November 30, 2014, and $3,000,000 thereafter, as well as providing limitations on dividends, additional indebtedness, and certain other changes.
	On January 7, 2015, Colorado Business Bank provided the Company with notice of a non-monetary event of default concerning the Company’s violation of the minimum tangible equity capital covenant set forth in the loan agreement. On March 17, 2015, iSatori reached a preliminary agreement with their primary banking institution, Colorado Business Bank ("CoBiz"), in which the loan agreement and covenants will be modified and the Company will no longer be in forbearance. iSatori and CoBiz have agreed on the principal terms of the arrangement and are currently awaiting documentation from their respective legal teams. The Company has, and will continue to, enter into discussions with certain material vendors, offering early pay discounts to improve the timing of accounts receivable collection. In addition, the Company has, and will continue to, enter into discussions with certain material suppliers concerning extended credit terms to improve the flexibility of the Company's cash management program. These actions, combined with the pending agreement with CoBiz, will help ensure the Company's liquidity and compliance with its loan covenants.
	The Company’s prior line of credit with Colorado Business Bank West of Denver, Colorado provided a revolving commitment to the Company in the amount of $1,500,000 and was in effect since its inception on July 16, 2012 and subsequent renewal on October 16, 2013 through the date of the renewal and expansion on August 27, 2014. Other terms of the former credit agreement were the same as those of the renewed and expanded credit agreement described above.
	The outstanding balance on the Company’s revolving line of credit as of December 31, 2014 and 2013 was $1,620,519 and $1,220,655, respectively.

Fair_Value_Measurements_and_Di

Fair Value Measurements and Disclosures	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements and Disclosures	Note 10 - Fair Value Measurements and Disclosures
	The Company follows ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for using fair value to measure assets and liabilities, and expands disclosures about fair value measurements. The statement establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of the inputs as follows:
	Level 1: Quoted prices are available in active markets for identical assets or liabilities.
	Level 2: Quoted prices in active markets for similar assets and liabilities that are observable for the asset or liability; or
	Level 3: Unobservable pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.
	ASC 820 requires financial assets and liabilities to be classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
	For the purposes of marketable securities where there is an active market, the Company uses the quoted prices available for the identical asset or liability. As of December 31, 2013, $108,228 assets held for sale valued using the Level 1 mark-to-market approach. As of December 31, 2014, the Company had $34,979 assets held for sale valued using the Level 1 mark-to-market approach.
	The inputs used in the fair value measurements categorized within Level 3 include the stock price at the valuation date, the exercise price of the warrant, the expected period of time the warrant will be outstanding, the annual volatility of the underlying stock price, the annual yield rate of quarterly dividends, and the risk free rate of interest relevant to the expected time period the warrant will be outstanding.
	The following table represents the Company’s warrant derivative liabilities that were accounted for at fair value on a recurring basis by level within the fair value hierarchy:
		31-Dec-14						31-Dec-13
		Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
		$	34,979	$	-	$	152,849	$	108,228	$	-	$	471,015
	Beginning of period		108,228		-		471,015		29,338		-		701,852
	Additions		-		-		-		-		-		-
	Deletions		-115,881		-		-		-36,103		-		-87,755
	Revisions		42,632		-		-318,166		114,993		-		-143,082
	End of period	$	34,979	$	-	$	152,849	$	108,228	$	-	$	471,015

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 11 – Subsequent Events
	Derivative Liability. During February 2015, the warrant issued to Breakwater Structured Growth Opportunity Fund, L.P for 420,549 shares, set up as the Derivative Liability on the Company’s balance sheet, was exercised and shares issued to the company.
	Bank Line of Credit. On March 17, 2015, iSatori reached a preliminary agreement with their primary banking institution, Colorado Business Bank ("CoBiz"), in which the loan agreement and covenants will be modified and the Company will no longer be in forbearance. iSatori and CoBiz have agreed on the principal terms of the arrangement and are currently awaiting documentation from their respective legal teams. The Company has, and will continue to, enter into discussions with certain material vendors, offering early pay discounts to improve the timing of accounts receivable collection. In addition, the Company has, and will continue to, enter into discussions with certain material suppliers concerning extended credit terms to improve the flexibility of the Company's cash management program. These actions, combined with the pending agreement with CoBiz, will help ensure the Company's liquidity and compliance with its loan covenants.
	New Investor Relations Program. During February 2015, the Company retained Self & Associates to expand and implement a more robust corporate communications and investor relations program for IFIT. Management is planning to begin a series of financial meetings in various key markets. In March, management will kick off meetings with members of the financial community in Southern California. These meetings will include several in Southern California from March 25 - 26 with meetings in LA and Santa Monica on March 25 and Newport Beach on March 26. Following Southern California, IFIT management will plan to visit the New York - New Jersey areas.

Accounting_Policies_Policies

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Organization and Nature of Business	Organization and Nature of Business
	iSatori,Inc. (the “Company”) was incorporated under the laws of the state of Delaware on June 29, 2012. The trading symbol of the Company on OTCBB is “IFIT”.
	The Company is engaged in researching, designing, developing, contracting for the manufacture, marketing, selling and distributing of various branded nutritional and dietary supplement products for the general nutrition market. The “general nutrition market” may include such activities as body-building, physique enhancement (increase of lean body mass and decrease in fat mass) and enhanced athletic performance through increased strength and/or endurance and proper nutrition.
	The Company does engage from time to time in funding of clinical studies with the objective of discovering and/or validating claims of new, efficacious products for the Company’s relevant market as well as providing necessary and appropriate substantiation for any claims which the Company may use in its marketing and advertising. The Company markets products which are under its control and which are in some way proprietary to the Company. Some of the Company’s products are the subject of trademarks owned by the Company.
Basis of Presentation/Basis of Consolidation	Basis of Presentation
	The accompanying financial statements have been prepared on an accrual basis of accounting in accordance with Generally Accepted Accounting Principles in the United States (“GAAP”). The accompanying financial statements present the financial position and results of operations of the Company.
Financial Instruments	Financial Instruments
	The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Accordingly, cash and cash equivalents consist of petty cash, checking accounts and money market funds.
Fair Value Measurements	Fair Value Measurements
	Accounting Standards Codification (“ASC”) 820-10 establishes a framework for measuring the fair value of assets and liabilities and requires additional disclosure about fair value measurements. ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal (or most advantageous market) for the asset or liability in than orderly transaction between market participants at the measure date.
	The Company has a number of financial instruments, including cash, receivables, inventory, payables and debt obligations. The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued expenses, the line of credit and notes payable approximates their fair values because of the short maturity of these instruments. As further described in Note 7 the Company has issued warrants which are measured at fair value on a recurring basis and result in a long-term derivative liability on the balance sheet.
Trade Receivables and Credit Policy	Trade Receivables and Credit Policy
	Trade receivables are uncollateralized customer obligations due under normal trade terms requiring payment generally within 10-60 days from the invoice date. Accounts are considered delinquent when outstanding for more than seven days past due date. The Company does not have a policy of accruing interest on past due accounts. Payments on trade receivables are applied as instructed per the customer, or to the earliest unpaid invoices. The allowance for doubtful accounts represents an estimate of amounts considered uncollectible and is determined based on management’s historical collection experience, adverse situations that may affect the customer’s ability to repay, and prevailing economic conditions. Specific accounts deemed uncollectible are written off periodically with subsequent receipts on previously written off accounts credited to bad debt expense.
Inventory Valuation	Inventory Valuation
	Inventories of nutritional and dietary supplements are stated at lower of cost or market on a first-in, first-out (FIFO) basis.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost. Depreciation for financial accounting purposes is computed using the straight-line method over the estimated lives of the respective assets, ranging from three to ten years. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are thereafter removed from the respective accounts and any gain or loss is credited or charged to income.
Other Assets and Intangible Assets	Other Assets and Intangible Assets
	Other assets include intangible assets which are principally direct television advertising, websites, as well as deposits and are included in Deposits and other Assets. The Company periodically performs reviews of other assets including amortizable intangible and depreciable tangible assets, for impairment purposes using undiscounted cash flow methodology. Factors considered important that may trigger an impairment of assets review include, but are not necessarily limited to: significant changes in the manner of the use of its assets involving its strategy for its overall business; significant negative industry or economic trends; or underperforming business trends. These reviews may include an analysis of the Company’s current operations and capacity utilization in conjunction with an analysis of the markets in which the Company’s business is operating.
	Intangible assets are discussed below. Amortization for financial accounting purposes is computed using the straight-line method over the estimated useful lives of the respective assets which range from three to ten years.
Revenue Recognition	Revenue Recognition
	The Company operates predominantly as a distributor of its dietary supplement products through traditional large retailers and electronic intermediaries. Revenue from product sales is recognized upon transfer of title of the Company’s product to its customers. Net sales represent product sales less actual returns, allowances, discounts, and product promotions. Sales to direct customers have an unconditional money back guarantee for thirty to ninety days after the date of purchase. Sales to a select number of retail customers carry a “Sale or Return” Purchase agreement per the sales contract, where if minimum sales thresholds are not met within a required timeframe, the inventory will be returned to the Company for full credit. Other retail customers receive a percentage discount from invoice to cover any customer returns or damages they may incur.
	In addition, the Company provides allowances for sales returns based upon estimated and known returns. Product returns are recorded as a reduction of net revenues and as a reduction of the accounts receivable balance.
	The Company receives other revenues which includes but is not limited to shipping and handling charges which is charged to customers.
Cost of Sales	Cost of Sales
	The Company purchases its products directly from third party manufacturers. The Company’s cost of sales include product costs, including any associated materials used in production, cost of warehousing and distribution. Included in the cost of sales are transit freight shipping and handling costs that are incurred by the Company.
Income Taxes	Income Taxes
	The Company utilizes the asset and liability method of accounting for income taxes. Under this asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. See Note 6, “Income Taxes”.
	Since 2012 was the Company’s initial tax year, there are no prior federal or state tax returns subject to examination. Accordingly, the only taxable periods subject to examination by federal and state taxing authorities are the periods ended December 31, 2014, 2013 and 2012. Federal and state tax returns for the Company prior to the short form merger are open for the period ended December 31, 2011.
Leases	Leases
	The Company leases its headquarters facility the “headquarters lease”, comprising approximately 10,044 square feet, in Golden (metropolitan Denver), Colorado. The lease term expires January 31, 2017 and requires equal monthly payments over the remaining term.
	On November 1, 2014, the Company entered into a lease for approximately 17,026 square feet in Denver for its warehouse operations (the “warehouse lease”). The lease term expires on December 31, 2018 and calls for inflation-adjusted increasing payments over the remaining term.
	The Company also leases miscellaneous office and warehouse equipment. In most cases, management expects that in the normal course of business these leases will be renewed or replaced by other leases as applicable.
Marketing	Marketing
	The Company expenses all production costs related to advertising costs as they are incurred, including print, digital and television when the advertisement has been broadcast or otherwise finished and or distributed. The Company records website costs related to its direct-to-consumer advertisements in accordance with ASC 340-20 “Capitalized Advertising Costs”. In accordance with ASC 340-20, direct response advertising costs incurred should be reported as assets and should be amortized over the estimated period of the benefits, based on the proportion of current period revenue from the advertisements to probable future revenue. As of December 31, 2014 and December 31, 2013, the Company had deferred $0 and $7,651 respectively, related to such advertising costs. This amount was included in Deposits and other assets and was amortized over a one year period.
Research and Development Costs	Research and Development Costs
	Research and development costs, which include the funding of clinical research studies, as well as creation and development of new products, are expensed when incurred and are included in selling and marketing expense.
Distribution, Shipping and Handling Costs	Distribution, Shipping and Handling Costs
	Shipping costs on purchases and shipping and handling fees related to sales charged to customers are both included in cost of sales. As mentioned in Revenue Recognition, shipping and handling revenue billed customers are reflected in other revenues.
Concentration of Credit Risk	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentration of credit risk consist principally of temporary cash investments and trade accounts receivables. Concentrations of credit with respect to trade receivables are limited due to the large number of customers comprising the Company’s customer bases and their dispersion across different geographic locations.
	The Company maintains cash balances at one financial institution located in Colorado and one in California. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 per account. At times during the year, the Company’s bank balances have exceeded the FDIC limit. Management believes the risk of loss at such institutions to be minimal.
	During the year ended December 31, 2014, sales to three customers made up 57% of total product revenue, with each customer representing greater than 10% of product revenue on an individual basis. These customers’ combined accounts receivable balances were 51% of total accounts receivable as of December 31, 2014. During the year ended December 31, 2013, sales to three customers made up 58% of total product revenue, with each customer representing greater than 10% of product revenue on an individual basis. These customers’ combined accounts receivable balances were 73% of total accounts receivable as of December 31, 2013.
	During the year ended December 31, 2014, purchases from three vendors made up 63% of total inventory purchases. These vendors’ combined accounts payable balances were 44% of total accounts payable as of December 31, 2014. During the year ended December 31, 2013, purchases from two vendors made up 57% of total inventory purchases. These vendors’ combined accounts payable balances were 17% of total accounts payable as of December 31, 2013.
Use of Estimates	Use of Estimates
	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include but are not limited to the fair value determination of derivative instruments, NOL allowance, sales returns allowance, allowance for notes receivable and the realizable value of inventories.
Earnings (Loss) Per Share
	Earnings (Loss) Per Share
	Net earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.
	Since the Company reflected a net loss for the years ended December 31, 2014 and 2013, the effect of considering any common stock equivalents, if exercisable, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-15, Presentation of Financial Statements - Going Concern. The objective of ASU 2014-15 is to provide guidance on management’s responsibility to evaluate whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for fiscal years ending after December 15, 2016, and annual and interim periods thereafter. The Company is currently evaluating impact of the adoption of this standard and do not expect it to have a significant impact on its financial statements.
	In May 2014, the FASB issued ASU 2014-09, which establishes a comprehensive new revenue recognition standard designed to depict the transfer of goods or services to a customer in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under current revenue recognition guidance. The ASU allows for the use of either the full or modified retrospective transition method, and the standard will be effective for us in the first quarter of 2017 unless a deferral for adoption is provided by the FASB; early adoption is not permitted. The Company is currently evaluating which transition approach to use and the impact of the adoption of this standard on its financial statements.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Estimated Fair Value of Financial Instruments
		31-Dec-14					31-Dec-13
		Carrying			Fair Value		Carrying		Fair Value
		Value					Value
	Cash and cash equivalents	$	738,725		$	738,725	$	822,876	$	822,876
	Accounts Receivables	$	925,506		$	925,506	$	2,398,178	$	2,398,178
	Accounts payable	$	819,918		$	819,918	$	1,248,490	$	1,248,490
	Derivative liability	$	152,849		$	152,849	$	471,015	$	471,015
Trade Receivables and Credit Policy
		December 31,			December 31,
		2014			2013
	Trade Receivables	$	951,396		$	2,323,522
	Other	$	-25,890		$	74,656
	Allowance for doubtful accounts	$	0		$	0
	Totals	$	925,506		$	2,398,178
Inventory Valuation
		December 31,			December 31,
		2014			2013
	Labels and packaging	$	170,435		$	120,057
	Raw materials	$	308,333		$	207,320
	Finished goods	$	2,004,834		$	1,658,387
	Totals	$	2,483,602		$	1,985,764
Other Assets and Intangible Assets
		Balance at			Balance at
		31-Dec-14			31-Dec-13
	Amortized intangible assets:
	Website	$	38,355		$	38,355
	Patents	$	341		$	341
	Trademarks	$	100		$	100
	TOTAL	$	38,796		$	38,796
	Accumulated Amortization	$	-24,890		$	-12,090
	TOTAL	$	13,906		$	26,706
	Future Amortization for the years ending December 31:
	2015	$	12,785
	2016	$	1,121
Leases	Future Payments
	2015		$	169,993
	2016		$	174,350
	2017		$	102,748
	2018		$	100,199
	Total		$	547,290
Earnings (Loss) Per Share
			2014		2013
	In the money stock options		593,081		669,963
	In the money warrants		420,549		928,881
	Total common stock equivalents		13,689,208		13,862,892

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense Benefit	Income tax provision for the periods December 31, 2014 and December 31, 2013 consists of the following:
		12/31/14			12/31/13
	Current tax expense (benefit)
	Federal	$	67,026		$	18,438
	State		10,649			1,890
			77,675			20,328
	Deferred tax expense (benefit):
	Federal		185,106			-18,756
	State		15,916			1,256
			201,022			-17,500
	Total	$	278,697		$	2,828
Schedule of Effective Income Tax Reconciliation
		12/31/14		12/31/13
	Federal income taxes	35.00%		35.00%
	State income taxes	2.81%		2.18%
	Permanent items	-2.29%		-9.60%
	Current year losses not utilized	-61.04%		-27.90%
		25.51%		0.30%
Schedule of Deferred Tax Assets and Liabilities	The components of the deferred tax assets, net of deferred tax liabilities for each period are:
		12/31/14			12/31/13
	Inventory	$	42,109		$	32,709
	Allowance for doubtful accounts		32,132			26,506
	Deferred revenue		72,646			111,069
	Other		32,147			9,865
	Valuation allowance		-167,394			-
	Current Deferred Tax Assets		11,640			180,149
	Net operating loss		772,088			410,140
	Foreign tax credits		29,211			-
	Fair value of derivatives		58,097			179,030
	Share based compensation		21,505			21,589
	Property and equipment		22,366			-
	Valuation allowance		-844,543			-410,140
	Long term deferred tax assets		58,724			200,619
	Total deferred tax assets		70,364			380,768
	Unrealized gain on marketable securities		-13,295			-41,137
	Prepaid expenses		-55,659			-85,931
	Current deferred tax liabilities		-68,954			-127,068
	Property & equipment		-			-43,853
	Goodwill and other intangibles		-1,410			-8,825
	Long term deferred tax liabilities		-1,410			-52,678
	Total deferred tax liabilities		-70,364			-179,746
	Net Deferred tax asset	$	-		$	201,022
Summary of Operating Loss Carryforwards	The NOLs are projected to expire as follows:
	2032		$	434,814
	2033			466,786
	2034			1,129,703
			$	2,031,303

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of Share-based Payment Award, Warrants Valuation Assumptions	The Black-Scholes assumptions used when the warrants were issued are as follows:
		FY 2013
	Exercise price	$	2.25
	Expected dividends		0	%
	Expected volatility		45.95-48.97	%
	Risk fee interest rate		0.72-1.42	%
	Expected life		5 years
	Expected forfeiture		0	%
	The Black-Scholes assumptions used when the options were issued are as follows:
			FY 2014				FY 2013
	Exercise price	$	2.22-2.50			$	2.1
	Expected dividends		0	%			0	%
	Expected volatility		35.22	%			45.95	%
	Risk fee interest rate		2.13-2.41	%			2.26	%
	Expected life of option		6.08-6.33 years				5.5-6.5 years
	Expected forfeiture		0	%			0	%
Schedule of Share-based Compensation Stock Warrants Activity	The following is a summary of the Company’s warrant activity:
			Warrants		Weighted Average			Weighted Average
					Exercise Price			Remaining
								Contractual Life
	Balance – December 31, 2012		225,000			2.36		6.08 years
	Granted		350,000		$	2.25		4.42 years
	Exercised		-			-
	Forfeited/cancelled		-			-
	Balance – December 31, 2013		575,000			2.29		5.05 years
	Granted		-			-
	Exercised		-			-
	Forfeited/Cancelled		-			-
	Balance – December 31, 2014 – outstanding		575,000		$	2.29		4.05 years
	Balance – December 31, 2014 – exercisable		575,000		$	2.29		4.05 years
Schedule of Share-based Compensation Stock Option Activity	The following is a summary of the Company’s stock option activity:
			Options		Weighted Average			Weighted Average
					Exercise Price			Remaining
								Contractual Life
	Balance – December 31, 2012		828,174			0.683		9.14 years
	Granted		50,000		$	2.1		9.75 years
	Exercised		-137,577			0.621
	Forfeited/cancelled		-9,908			2.25
	Balance – December 31, 2013		730,689		$	0.771		8.30 years
	Granted		16,000		$	2.4		9.75 years
	Exercised
	Forfeited/cancelled		-16,000		$	2.4		9.75 years
	Balance – December 31, 2014 – outstanding		730,689		$	0.771		7.30 years
	Balance – December 31, 2014 – exercisable		637,159			0.683		7.25 years
	Outstanding options held by related parties – 2014		730,689
	Exercisable options held by related parties – 2014		637,159

Convertible_Preferred_Stock_Ta

Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Convertible Preferred Stock
Schedule of Convertible Preferred Stock
		Par Value		Shares	Liquidation
				Outstanding	Preference
	Series A $20	$	95	9,500	$	190,000
	Series D $20		130	13,000		260,000
		$	225	22,500	$	450,000

Fair_Value_Measurements_and_Di1

Fair Value Measurements and Disclosures (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Liabilities Measured on Recurring Basis
		31-Dec-14						31-Dec-13
		Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
		$	34,979	$	-	$	152,849	$	108,228	$	-	$	471,015
	Beginning of period		108,228		-		471,015		29,338		-		701,852
	Additions		-		-		-		-		-		-
	Deletions		-115,881		-		-		-36,103		-		-87,755
	Revisions		42,632		-		-318,166		114,993		-		-143,082
	End of period	$	34,979	$	-	$	152,849	$	108,228	$	-	$	471,015

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Fair Value Measurements (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value of Assets and Liabilities
Cash and cash equivalents, carrying value	$738,725	$822,876	$1,655,453
Receivables, carrying value	925,506	2,398,178
Accounts Payable, carrying value	819,918	1,248,490
Derivative Liability, carrying value	152,849	471,015
Cash and cash equivalents, fair value	738,725	822,876
Receivables, fair value	925,506	2,398,178
Accounts Payable, fair value	819,918	1,248,490
Derivative Liability, fair value	$152,849	$471,015

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Trade Receivables and Credit Policy (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Trade Receivables
Trade Receivables	$951,396	$2,323,522
Other	-25,890	74,656
Allowance for doubtful accounts	0	0
Total trade receivables, net	$925,506	$2,398,178

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Inventory Valuation (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory Valuation
Labels and packaging	$170,435	$120,057
Raw materials	308,333	207,320
Finished goods	2,004,834	1,658,387
Total inventories	$2,483,602	$1,985,764

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Intangible Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Amortized intangible assets:
Website	$38,355	$38,355
Patents	341	341
Trademarks	100	100
Total intangible assets, gross	38,796	38,796
Accumulated Amortization	-24,890	-12,090
Total intangible assets, net	$13,906	$26,706

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Future Amortization of Intangibles (Details) (USD $)	Dec. 31, 2014
Future Amortization of Intangible Assets
Year 2015	$12,785
Year 2016	$1,121

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Future Lease Payments (Details) (USD $)	Dec. 31, 2014
Future Lease Payments
2015	$169,993
2016	174,350
2017	102,748
2018	100,199
Operating leases, future minimum payments	$547,290

Summary_of_Significant_Account8

Summary of Significant Accounting Policies - Antidilutive Securities (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share calculation	593,081	669,963
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share calculation	420,549	928,881
Common Stock Equivalents
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share calculation	13,689,208	13,862,892

Summary_of_Significant_Account9

Summary of Significant Accounting Policies - Concentration of Credit Risk (Details Narrative)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Customer Concentration Risk | Product Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	57.00%	58.00%
Customer Concentration Risk | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	51.00%	73.00%
Vendor Concentration Risk | Inventory Purchases
Concentration Risk [Line Items]
Concentration risk, percentage	63.00%	57.00%
Vendor Concentration Risk | Accounts Payable
Concentration Risk [Line Items]
Concentration risk, percentage	44.00%	17.00%

Recovered_Sheet1

Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Sales Returns and Allowances
Allowance for customer returns	$85,000	$70,000
Receivables
Note receivable	81,634
Note receivable, additional disclosure	The predecessor company disposed of a dormant product line of vitamins in December 2010. As part of the consideration in this divestiture, the Company received from the purchaser of this product line an unsecured note in the amount of $170,000. The original note was due to be repaid on or before March 2014, where interest accrued principally at an annual rate of 5%, based upon the initial $170,000 principal and was payable monthly. As of March 31, 2013, the note was novated and a new promissory note was issued to reflect a modification in the payment terms, which includes no interest.
Note receivable, maturity date	1-May-17
Property and Equipment
Depreciation expense	65,774	83,450
Intangible Assets
Amortization expense	12,800	11,698
Revenue Recognition
Revenue recognition, returns, allowances and discounts	2,656,122	2,114,060
Leases
Leases, future payments	547,290
Marketing
Marketing, deferred advertising costs	0	7,651
Marketing, expense	1,500,362	2,232,548
Research and Development Expense
Research and development costs	99,676	162,297
Headquarters Lease
Leases
Leases, rent expense	82,863	82,863
Leases, expiration date	31-Jan-17
Leases, future payments	172,632
Warehouse Lease
Leases
Leases, rent expense	0
Leases, expiration date	31-Dec-18
Leases, future payments	$374,658
Minimum
Intangible Assets
Estimated useful lives	3 years
Maximum
Intangible Assets
Estimated useful lives	10 years

Endorsement_Spokesperson_Consu1

Endorsement / Spokesperson / Consulting Agreements (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Marketing and Advertising Expense [Abstract]
Endorsement / Spokesperson / Consulting, expense	$102,650	$161,950
Future marketing contractual commitments	$18,000

Income_Taxes_Income_Tax_Provis

Income Taxes - Income Tax Provision (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current tax expense (benefit)
Federal	$67,026	$18,438
State	10,649	1,890
Current tax expense (benefit)	77,675	20,328
Deferred tax expense (benefit)
Federal	185,106	-18,756
State	15,916	1,256
Deferred tax expense (benefit)	201,022	-17,500
Total tax provision (benefit)	$278,697	$2,828

Income_Taxes_Income_Tax_Rate_R

Income Taxes - Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal Income Taxes	35.00%	35.00%
State Income Taxes	2.81%	2.18%
Permanent Items	-2.29%	-9.60%
Current Year Losses not utilized	-61.04%	-27.90%
Effective Income Tax Rate Reconciliation	25.51%	0.30%

Income_Taxes_Deferred_Taxes_De

Income Taxes - Deferred Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax asset
Inventory	$42,109	$32,709
Allowance for customer returns	32,132	26,506
Deferred revenue	72,646	111,069
Other	32,147	9,865
Valuation allowance	-167,394	0
Current Deferred Tax Assets	11,640	180,149
Net Operating Loss	772,088	410,140
Foreign tax credits	29,211	0
Fair value of derivatives	58,097	179,030
Share Based Compensation	21,505	21,589
Property and equipment	22,366	0
Valuation allowance	-844,543	-410,140
Long term deferred tax assets	58,724	200,619
Total deferred tax assets	70,364	380,768
Deferred tax liability
Unrealized gain on marketable securities	-13,295	-41,137
Prepaid expenses	-55,659	-85,931
Current deferred tax liabilities	-68,954	-127,068
Property & equipment	0	-43,853
Goodwill and other intangibles	-1,410	-8,825
Long term deferred tax liabilities	-1,410	-52,678
Total deferred tax liabilities	-70,364	-179,746
Net deferred tax asset	$0	$201,022

Income_Taxes_Operating_Loss_Ca

Income Taxes - Operating Loss Carryforward Expirations (Details) (USD $)	Dec. 31, 2034	Dec. 31, 2033	Dec. 31, 2032
Income Tax Disclosure [Abstract]
Net operating losses expiration	$1,129,703	$466,786	$434,814

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Income tax benefit (expense)	$278,697	$2,828
Effective statutory federal income tax rate	35.00%	35.00%
Net operating loss carryforward	2,031,303
NOL from Predecessor Company
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	8,208,000
NOL from iSatori
Operating Loss Carryforwards [Line Items]
Valuation allowance	$844,543	$410,140

Stockholders_Equity_Fair_Value

Stockholders' Equity - Fair Value Assumptions Warrants and Stock Options (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrants
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price		$2.25
Expected dividends		0.00%
Expected volatility, minimum		45.95%
Expected volatility, maximum		48.97%
Risk free interest rate, minimum		0.72%
Risk free interest rate, maximum		1.42%
Expected life of option		5 years
Expected forfeiture		0.00%
Stock Options
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price		$2.10
Exercise price, lower range limit	$2.22
Exercise price, upper range limit	$2.50
Expected dividends	0.00%	0.00%
Expected volatility	35.22%	45.95%
Risk free interest rate		2.26%
Risk free interest rate, minimum	2.13%
Risk free interest rate, maximum	2.41%
Expected life of option	6.08-6.33 years	5.5-6.5 years
Expected forfeiture	0.00%	0.00%

Stockholders_Equity_Stock_Opti

Stockholders' Equity - Stock Option Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Stock options outstanding, beginning of period	730,689	828,174
Stock options granted	16,000	50,000
Stock options exercised		-137,577
Stock options forfeited/cancelled	-16,000	-9,908
Stock options outstanding, end of period	730,689	730,689
Stock options exercisable, end of period	637,159
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price outstanding, beginning of period	$0.77	$0.68
Weighted average exercise price forfeited/cancelled	$2.40	$2.25
Weighted average exercise price granted	$2.40	$2.10
Weighted average exercise price exercised		$0.62
Weighted average exercise price outstanding, end of period	$0.77	$0.77
Weighted average exercise price exercisable, end of period	$0.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining contractual life outstanding, granted	9 years 9 months	9 years 9 months
Weighted average remaining contractual life outstanding, forfeited/cancelled	9 years 9 months
Weighted average remaining contractual life outstanding, end of period	7 years 4 months	8 years 4 months
Weighted average remaining contractual life exercisable, end of period	7 years 3 months

Stockholders_Equity_Stock_Warr

Stockholders' Equity - Stock Warrant Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Warrants outstanding, beginning of period	575,000	225,000
Warrants granted		350,000
Warrants outstanding, end of period	575,000	575,000
Warrants exercisable, end of period		575,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price
Warrants, weighted average exercise price outstanding, beginning of period	$2.29	$2.36
Warrants, weighted average exercise price granted		$2.25
Warrants, weighted average exercise price outstanding, end of period	$2.29	$2.29
Warrants, weighted average exercise price exercisable, end of period	$2.29
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures
Warrants, weighted average remaining contractual life outstanding, beginning of period	5 years 1 month	6 years 1 month
Warrants, weighted average remaining contractual life, granted		4 years 5 months
Warrants, weighted average remaining contractual life outstanding, end of period	4 years 1 month	5 years 1 month
Warrants, weighted average remaining contractual life exercisable, end of period	4 years 1 month

Stockholders_Equity_Details_Na

Stockholders' Equity (Details Narrative) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Feb. 28, 2014	Jan. 31, 2014	Sep. 30, 2013	Dec. 31, 2012	Feb. 10, 2014	Jan. 02, 2014	Sep. 17, 2013
Class of Stock [Line Items]
Stock options issued	16,000	50,000
Stock options forfeited	-16,000	-9,908
Common stock, outstanding	12,909,278	12,879,651
Common stock, par value in dollars	$0.01	$0.01
Stock options exercise price	$0.77	$0.77					$0.68
Stock warrants granted		350,000
Weighted average expected term	5 years 1 month	6 years 1 month
Share-based compensation expense	$10,328
Stock option compensation expense recognized	12,619
Other operating income	318,166	143,082
Decrease in warrant derivative liability due to warrant exercise	0	87,755
Stock warrants assumed in acquisition	The Company assumed the 1,069,587 outstanding warrants to purchase shares of Common Stock which were issued by Integrated in fiscal years 2009 and before. Of these, 17,230 expired on July 29, 2012 and the remainder expired on May 31, 2014.
Fair value of options granted	3,363	30,985
Warrants | Optivest Global Partners, LLC
Class of Stock [Line Items]
Stock warrants granted		250,000
Stock warrant, exercise price		$2.25
Stock options and warrants granted expiration date		16-Jul-18
Stock options and warrants vesting period		Fully vested
Warrants | Microcap Headlines, Inc.
Class of Stock [Line Items]
Stock warrants granted		100,000
Stock warrant, exercise price		$2.25
Stock options and warrants granted expiration date		1-Jan-18
Stock options and warrants vesting period		These warrants were subject to conditional vesting schedule in one-fourth (quarterly) increments, subject to the CompanyBs sole discretion. The first increment was granted and fully vested on January 1, 2013, the second increment was granted and fully vested on April 1, 2013, the third increment was granted and fully vested on July 1, 2013, and the fourth increment was granted and fully vested on October 1, 2013
Warrants | Breakwater Structured Growth Opportunity Fund, L.P.
Class of Stock [Line Items]
Stock warrants granted			420,549
Stock warrant, rights			On July 15, 2011, the company issued warrants to purchase 3% of fully diluted shares of the common stock of the Company to Breakwater Structured Growth Opportunity Fund, L.P., with an imputed exercise price equal to approximately one-hundredth of a dollar in connection with a $1.025 million subordinated mezzanine loan arrangements.
Stock options and warrants granted expiration date			15-Jun-16
Stock options and warrants vesting period			Fully vested
Stock value, lattice model method			The Company used a lattice model in developing a fair value for the Breakwater warrant obligation at December 31, 2014, using a quoted stock value of $.375 per share, which represents a discount of 50% from the closing stock price. This reduction was based on the application of a discount for lack of liquidity.
Discount assumption			50.00%
Risk free interest rate			0.67%
Stock price, movement range			1.053 to .950
Risk neutral probabilities, range			.488 to .512
Weighted average expected term			1 year 9 months
Weighted average expected volatility			37.13%
Business Development Consultant
Class of Stock [Line Items]
Common stock issued for services	7,500
Stock price	$2.17
Share-based compensation expense	16,275
Stock Options | Employees
Class of Stock [Line Items]
Stock options issued				6,000	10,000	50,000
Stock options forfeited				6,000	10,000
Stock options exercise price								$2.22	$2.50	$2.10
Stock options and warrants granted expiration date				10-Feb-24	15-Oct-23	17-Sep-23
Stock options and warrants vesting period				Three year vesting schedules of 1/3 each year through February 2017.	Three year vesting schedules of 1/3 each year through October 2016.	Three year vesting schedules of 1/3 each year through September 2015
Restricted Stock
Class of Stock [Line Items]
Share-based compensation expense	16,568
Restricted stock issued	22,127
Restricted stock expense recognized from prior issuances	$9,212

Convertible_Preferred_Stock_De

Convertible Preferred Stock (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Par value	$225	$225
Shares outstanding	22,500	22,500
Liquidation preference	450,000	450,000
Series A $20
Class of Stock [Line Items]
Par value	95
Shares outstanding	9,500
Liquidation preference	190,000
Series D $20
Class of Stock [Line Items]
Par value	130
Shares outstanding	13,000
Liquidation preference	$260,000

Convertible_Preferred_Stock_De1

Convertible Preferred Stock (Details Narrative)	12 Months Ended
	Dec. 31, 2014
Convertible Preferred Stock
Convertible preferred stock conversion terms	Each share of the Series A Preferred may, at the option of the Company, be converted into the equivalent of one-fifth (1/5th) of a share of common stock at any time after (i) the closing bid price of the common stock is at least $2.00 for at least 20 trading days during any 30 consecutive trading day period, and (ii) the shares of common stock to be received on conversion have been registered or otherwise qualified for sale under applicable securities laws. The holders of the Series A Preferred have the right to convert each share into the equivalent of one-fifth (1/5th) of a share of common stock at any time. Upon any liquidation, dissolution, or winding up of the Company, the holders of the Series A Preferred are entitled to receive $20 per share before the holders of common stock are entitled to receive any distribution. In the event the Company enters into any consolidation, merger or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or other securities, each share of Series A Preferred will at the same time be similarly exchanged or changed into such consideration as is equal to four times the amount of consideration to be received for each share of common stock. Holders of the Series D Preferred are entitled to receive, out of funds of the company legally available, dividends at the annual rate of $1.80 per annum per share. The Company may redeem the Series D Preferred upon not less than 30 days' notice, in whole or in part, for an amount of $20 per share plus all accrued but unpaid dividends applicable to such share. After notice and prior to the expiration of the 30-day notice period, holders of the Series D Preferred will have the option to convert the Series D Preferred into common stock prior to the redemption. Each share of the Series D Preferred may, at the option of the Company, be converted into the number of shares of common stock as determined by dividing $20 plus any accrued and unpaid dividends on such share by $80 at any time after (i) the closing bid price of the common stock exceeds $200.00 for 20 consecutive trading days, and (ii) the Company has sustained positive earnings per share of common stock for the two previous fiscal quarters. The holders of the Series D Preferred have the right to convert each share at any time into the number of shares of common stock as determined by dividing $20 plus any accrued and unpaid dividends on such share by $80. The holders of the Series D Preferred are entitled to receive $20 per share plus any accrued and unpaid dividends on such share before the holders of common stock are entitled to receive any distribution. In the event the Company enters into any consolidation, merger or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or other securities, each share of Series D Preferred will at the same time be similarly exchanged or changed into the aggregate amount of stock as would have been received had the holder converted such shares immediately prior to the transaction.

Revolving_Line_of_Credit_and_R1

Revolving Line of Credit and Related Interest (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 16, 2012
Line Of Credit Facility
Line of Credit	$2,000,000		$1,500,000
Line of Credit, maturity date	16-Nov-15
Line of Credit, interest rate description	The principal balance will note bear interest at the one month USD LIBOR rate measured not more often than once per month (the "Index"). Interest on any unpaid balance will bear interest at the Index plus 3.750% with a minimum interest rate of 4.00% per annum and is payable monthly.
Line of Credit, covenant terms	The agreement requires the Company to comply with certain affirmative covenants, including a minimum current ratio of 1.5 to 1, a maximum leverage ratio of 2 to 1, and minimum tangible equity capital of $2,750,000 through November 30, 2014, and $3,000,000 thereafter, as well as providing limitations on dividends, additional indebtedness, and certain other changes.
Line of Credit, balance outstanding	$1,620,519	$1,220,655

Fair_Value_Measurements_and_Di2

Fair Value Measurements and Disclosures (Details) (Derivative Financial Instruments, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Inputs - Level 1
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant derivative liability, beginning of year	$108,228	$29,338
Warrant derivative liability, deletions	-115,881	-36,103
Warrant derivative liability, revisions	42,632	114,993
Warrant derivative liability, end of year	34,979	108,228
Fair Value Inputs - Level 2
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant derivative liability, beginning of year	0	0
Warrant derivative liability, deletions	0	0
Warrant derivative liability, revisions	0	0
Warrant derivative liability, end of year	0	0
Fair Value Inputs - Level 3
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant derivative liability, beginning of year	471,015	701,852
Warrant derivative liability, deletions	0	-87,755
Warrant derivative liability, revisions	-318,166	-143,082
Warrant derivative liability, end of year	$152,849	$471,015

Fair_Value_Measurements_and_Di3

Fair Value Measurements and Disclosures (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Assets held for sale	$34,979	$108,228

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative)	12 Months Ended	1 Months Ended
	Dec. 31, 2013	Feb. 28, 2015
Subsequent Event [Line Items]
Warrants issued	350,000
Subsequent Event | Derivative Liability
Subsequent Event [Line Items]
Warrants issued		420,549